Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting

  Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and
  Care at Annual ASH Meeting

  – New, Interim Phase 3 Data Highlight Prolonged Half-Life of ELOCTATE™ and
                        ALPROLIX™ in Young Children –

 – 10 Abstracts, Including Oral Presentation, Highlight Data from Hemophilia
                      Research and Development Program –

ASH 2013

Business Wire

CAMBRIDGE, Mass. -- December 3, 2013

Biogen Idec (NASDAQ: BIIB) will present new data from its hemophilia clinical
development and research programs at the 55^th Annual Meeting of the American
Society of Hematology (ASH), taking place in New Orleans, December 7-10.
Reflecting Biogen Idec’s commitment to transform hemophilia care, researchers
will discuss 10 abstracts covering the breadth of the company’s comprehensive
basic and clinical research programs. This includes new, interim data from
Phase 3 studies in pediatric populations evaluating the company’s
investigational long-lasting recombinant factor VIII Fc fusion protein
candidate, ELOCTATE^TM, for hemophilia A and factor IX Fc fusion protein
candidate, ALPROLIX^TM, for hemophilia B.

“These new data from our groundbreaking research and development programs
demonstrate our commitment to improving hemophilia treatment,” said Glenn
Pierce, M.D., Ph.D., senior vice president of Global Medical Affairs and chief
medical officer at Biogen Idec’s hemophilia therapeutic area. “We are excited
to share our findings with physicians on the front lines of hemophilia
management to further the understanding of the disorder.”

The titles of key Biogen Idec presentations are as follows:

ELOCTATE

  *Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc)
    in Pediatric Subjects with Hemophilia A: An Interim Analysis of the Kids
    A-LONG Study - Poster #3609 – Monday, December 9 – 6:00-8:00 PM (CST)
  *Dosing Long-Lasting Recombinant Factor VIII Fc Fusion Protein: Experience
    in the A-LONG Study - Poster #3598 – Monday, December 9 – 6:00-8:00 PM
    (CST)
  *The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In
    Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc
    Fusion Protein - Poster #3590 – Monday, December 9 – 6:00-8:00 PM (CST)

ALPROLIX

  *Association of Bleeding Tendency with Time Under Target FIX Activity
    Levels in Severe Hemophilia B Patients Treated with Recombinant Factor IX
    Fc Fusion Protein - Poster #2349 – Sunday, December 8 – 6:30-8:30 PM (CST)
  *Pharmacokinetics, Safety and Efficacy of Long-lasting Recombinant Factor
    IX Fc Fusion Protein (rFIXFc) in Adolescent Subjects with Hemophilia B: A
    Subgroup Analysis of the B-LONG Study - Poster #2350 – Sunday, December 8
    – 6:30-8:30 PM (CST)
  *Pharmacokinetics of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in
    Pediatric Subjects with Hemophilia B: An Interim Analysis of the Kids
    B-LONG Study - Poster #3599 – Monday, December 9 – 6:00-8:00 PM (CST)

Hemophilia Health Outcomes Research

  *Psychometric Evaluation of Health-Related Quality of Life Data from the
    A-LONG and B-LONG Hemophilia Clinical Trials - Oral Presentation/Abstract
    #423 – Monday, December 9 – 11:00 AM (CST)

Nonclinical Research

  *Evidence for Flexible Tethering of Fc to FVIII in Recombinant FVIII-Fc
    Fusion Protein rFVIIIFc - Poster #1102 – Saturday, December 7 – 5:30-7:30
    PM (CST)
  *Immunohistochemical Staining of rFVIIIFc and rFVIII in Liver Cells
    Differentiates between a VWF-Dependent and Independent Clearance Pathway
    in Mice - Poster #2331 – Sunday, December 8 – 6:30-8:30 PM (CST)
  *An Immunodeficient Mice Model with Circulating Human Platelets to Evaluate
    the Platelet Clearance and Pharmacokinetics of Platelet-targeted
    Coagulator Factor VIIa - Abstract #2345 – Sunday, December 8 – 6:30-8:30
    PM (CST)

Full session details and data abstracts for the 2013 Annual Meeting can be
found on the ASH website at
http://www.hematology.org/Meetings/Annual-Meeting/; full-text abstracts will
be published in the December 6 issue of Blood, the journal of ASH.

Regulatory applications for ELOCTATE and ALPROLIX are currently under review
in several countries including the U.S., Canada and Australia.

About the Fc Fusion Technology Platform

ELOCTATE and ALPROLIX were developed using Fc fusion technology, which takes
advantage of a naturally occurring pathway that delays the breakdown of IgG1
(protein commonly found in the body) by recycling it back into the
bloodstream. This technology is thought to be responsible for the prolonged
time that ELOCTATE and ALPROLIX circulate in the body. While Fc fusion is an
established technology that has been used for more than 15 years, Biogen Idec
is the only company to apply it in hemophilia.

About Hemophilia

Hemophilia is a rare, inherited disorder in which the ability of a person’s
blood to clot is impaired. There are different types of hemophilia depending
on which clotting protein, or factor, is missing or reduced, including
hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency).
Hemophilia A occurs in about one in 5,000 male births annually, affecting
about 16,000 people in the U.S. Hemophilia B is less common, accounting for
about one in 25,000 male births annually, and approximately 3,000 people in
the U.S. Both forms of hemophilia occur more rarely in females.

People with hemophilia can experience bleeding episodes that can cause pain,
irreversible joint damage and life-threatening hemorrhages. Prophylactic
infusions of factor VIII or IX can restore the coagulation process, as well as
reduce or prevent new bleeding episodes. The Medical and Scientific Advisory
Council of the National Hemophilia Foundation recommends prophylaxis as the
optimal therapy for people with severe hemophilia.

About theBiogen Idecand Sobi Collaboration

Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the
development and commercialization of ELOCTATE for hemophilia A and ALPROLIX
for hemophilia B. Biogen Idec leads development, has manufacturing rights, and
has commercialization rights in North America and all other regions excluding
the Sobi territory. Sobi has the right to opt in to assume final development
and commercialization in Europe (including Russia), the Middle East and
Northern Africa.

AboutBiogen Idec

Through cutting-edge science and medicine,Biogen Idecdiscovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978,Biogen Idecis the world’s oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than$5 billionin annual revenues. For product
labeling, press releases and additional information about the company, please
visit www.biogenidec.com.

Biogen Idec Safe Harbor

This press release contains forward-looking statements, including statements
about the potential advances, impact and therapeutic effect of ELOCTATE and
ALPROLIX, our investigational long-lasting recombinant factor product
candidates. These statements may be identified by words such as "believe,"
"expect," "may," "plan," "potential," "will" and similar expressions, and are
based on our current beliefs and expectations. Drug development and
commercialization involve a high degree of risk. Factors which could cause
actual results to differ materially from our current expectations include the
risk that unexpected concerns may arise from additional data or analysis,
regulatory authorities may require additional data or information or further
studies, or may fail to approve or may delay approval of our drug candidates,
or we may encounter other unexpected hurdles. For more detailed information on
the risks and uncertainties associated with our drug development and
commercialization activities, please review the Risk Factors section of our
most recent annual or quarterly report filed with the Securities and Exchange
Commission. Any forward-looking statements speak only as of the date of this
press release and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or
otherwise.

Contact:

Biogen Idec
Media Contact:
Todd Cooper, +1-781-464-3260
public.affairs@biogenidec.com
or
Investor Relations Contact:
Ben Strain, +1-781-464-2442
IR@biogenidec.com
 
Press spacebar to pause and continue. Press esc to stop.